Evidence map›Paper›PMID 41605892›Full record

ReviewSignal transduction and targeted therapy2026

Deciphering the regulatory landscape of enhancer RNAs in health and disease.

Qian Wang, Peter Ten Dijke, Chuannan Fan

Abstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. 3D Genome Engineering Using CRISPR/dCas Systems.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Frontiers in cellular and infection microbiology · 2026
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qian WangOncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands. q.wang@lumc.nl.
Peter Ten DijkeOncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands. p.ten_dijke@lumc.nl.
Chuannan FanOncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands. c.fan@lumc.nl.ORCID http://orcid.org/0000-0001-8754-4913

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enhancers are distal cis-regulatory elements that orchestrate spatiotemporal gene expression patterns in response to developmental cues and environmental stimuli. Genetic and epigenetic alterations in enhancers are associated with the initiation and progression of human diseases, including cancers. Over the past few decades, accumulating evidence has revealed that a class of nascent RNA transcripts, known as enhancer RNAs (eRNAs), is broadly transcribed from active enhancers. These eRNA species contribute to complex and dynamic gene regulatory networks under both physiological and pathological conditions through diverse mechanisms. Notably, dysregulated eRNA expression has been reported across various cancer types and is often correlated with patient survival outcomes. Consequently, eRNAs are emerging as promising biomarkers and therapeutic targets for cancer treatment. This review provides a comprehensive summary of the current understanding of eRNAs and their mechanisms of action in gene regulation. We discuss the critical roles of eRNAs in both health and disease and highlight their diagnostic and prognostic value, as well as their therapeutic potential in cancer. Additionally, we review current strategies for targeting RNA transcripts, including eRNAs, and discuss the major challenges in developing eRNA-targeted therapies. Finally, we propose future directions for advancing eRNA-based interventions in the treatment of human diseases, including cancer.

Indexed as

Enhancer Elements, GeneticEnhancer RNAsGene Expression Regulation, NeoplasticGene Regulatory NetworksNeoplasmsAnimalsEpigenesis, GeneticHumansEnhancer RNAs

Identifiers

PMID41605892
PMCPMC12852191

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.